Improving management of type 2 diabetes mellitus: 5. Thiazolidinediones

Hospital Practice

Volumn 35, Issue 1, 2000, Pages 123-132

  Samraj, George P N ^a,b   Kuritzky, Louis ^a,b   Quillen, David M ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; BIGUANIDE DERIVATIVE; COLESTYRAMINE; CREATINE KINASE; CYCLOSPORIN; CYTOCHROME P450; GLUCOSE TRANSPORTER; HEMOGLOBIN A1C; INSULIN; KETOCONAZOLE; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ANEMIA; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DRUG ABSORPTION; DRUG HALF LIFE; DRUG MECHANISM; EDEMA; GLUCOSE TRANSPORT; HUMAN; HYPERTENSION; INSULIN SENSITIVITY; LIPID METABOLISM; LIVER FUNCTION; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OVULATION; PATIENT SELECTION; REVIEW; THROMBOSIS; WEIGHT GAIN;

EID: 0034650747     PISSN: 87502836     EISSN: None     Source Type: Journal    
DOI: 10.1080/21548331.2000.11443973     Document Type: Review

References (7)

1. American Diabetes Association. Implications of the United Kingdom Prospective Diabetes Study. Diabetes Care 21:2180, 1998
2. Gitlin N et al. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone. Ann Intern Med 129:36, 1998
3. Imano E et al. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy. Diabetes Care 21:2135, 1998
4. Inoue Y et al. Lack of effect of CS-045, a new antidiabetic agent on insulin secretion in the remnant pancreas after 90% pancreatectomy in rats. Diabetes Res Clin Pract 27:19, 1995
5. Inzucchi SE et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867, 1998
6. Plosker GL, Faulds D. Troglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs 57:409, 1999
7. Raskin P et al. A multicenter, randomized study of therapeutic effect of repaglinide combined with troglitazone in subjects with type 2 diabetes. Poster presentation, American Diabetic Association Annual Scientific Sessions, San Diego, Calif., June 19-22, 1999